JAMA Neurology

And they even found pesticides.

They found years ago, JAMA Neurology published that if they found DDT and derivatives in the brain of people, it was driving amyloid production.

So If you're thinking about it, it's trying to protect the brain.

But unfortunately, there's a side effect, right, which is it's interfering with neuronal communication.

It's precisely this gap that the HOPE trial was designed to address.

The late-breaking results of the HOPE trial were presented by Dr. Pol Camps-Renom at the most recent European Stroke Organization conference in May 2026 and were subsequently published in Jama Neurology in June of 2026.

Joining me now on the podcast is Dr. Camps-Renom himself to discuss post-reperfusion blood pressure management and the results of the HOPE trial.

Dr. Camps-Renom is an associate professor of neurology and stroke physician at Hospital de la Santa Cruz in Sant Pau in Barcelona, where he currently serves as the director of the stroke unit.

In fact, ADHD is one of the most common comorbidities in epilepsy.

with one study published in JAMA Neurology in 2025 that showed that people with seizures are about three to four times more likely to have ADHD compared with those people without seizures.

And interestingly, the most common ADHD presentation that we see among people with epilepsy or seizures is the inattentive type.

And why is this important? This is important because that means we're more likely to miss it.

So what is sort of currently known about that relationship? What is speculative? What do we know?

Well, what we know is, I know well what it takes to publish a paper in a leading scientific journal, and it turns out that about 10 or 12 years ago, a physician, Dr. Frank Lin, published a paper in the Archives of Neurology.

And he, with, um, the help of the National Institutes of Health, had, um, been spending something like 15 years, uh, following, uh, couple thousand patients as they progressed through, uh, life and, and going, uh, all the way, some of them obviously died, uh, over that period of time.

And that research paper, I think he won some awards for that research paper.

Not only that, had much increased risk of falls, of broken bones, and clinical depression as well.

And d- what happened as a result of that research?

Well, it was published in the Archives of Neurology, and I cite that, uh, publication in my book.

Mm.

A new treatment for post-therpetic neuralgia?

Yeah, so this is a study by Chen and colleagues published in JAMA Neurology in July that asks whether electroacupuncture is effective in decreasing pain in adults with post-traumatic neuralgia.

This was a pretty interesting and I think reasonably well done double blind trial from China.

They randomized adults between 45 and 75 years of age who had to have at least a four out of 10 level of pain from post-herpetic neuralgia.

From the JAMA Network, this is JAMA Neurology Author Interviews, conversations with authors exploring the latest clinical research, reviews, and opinions featured in JAMA Neurology.

Hello, and welcome to our listeners from around the world.

I'm Dr. Cynthia Armand, Associate Professor of Neurology at the Albert Einstein College of Medicine, Montefiore Medical Center, as well as JAMA Neurology Web Editor.

Today we are discussing Parkinson disease risk, specifically the role of smoking and exhaled carbon monoxide.

Our guest today is Dr. Zhangming Chen.

not because of safety factors, but because they're simply better drugs that, you know, from the standpoint of weight management.

But there are studies, there was a nice paper published in 2025 in JAMA Neurology from the VCU that looked at over a thousand individuals with idiopathic intracranial hypertension.

And 50% of those were on GLP-1 agonists and the other 50% were on no medication.

Now, indirectly, what they found was that over a longer period of time, with certainly a much larger study population, is that there was significant improvement in the papilledema, the headaches, visual function, fewer individuals requiring surgical intervention to manage their intracranial pressure.

So now let's go through a few interesting articles that might be worth the read that I saw from the past month.

First, there was kind of, I would say, kind of a controversial one out of JAMA Neurology in August that took a look at safety of anti-seizure medications during direct oral anticoagulant therapy in epilepsy.

So while strong enzyme-inducing anti-seizure medications were unsurprisingly associated with higher thromboembolic risk, I think we all knew that, but this cohort study also showed higher thromboembolic risk with levotiracetam, which is generally considered a safer option with low interaction potential.

So, you know, this did raise the level of concern there.